• Search
  • Helpdesk
  • Sales contact

Rare Disease case study

30 March 2023

Over 90% of rare diseases have no treatment… 

  • There are more than 6,000 known rare diseases…
  • Approximately 80% of them have a genetic component… 75% affect children…
  • And most rare diseases are chronic conditions, many of which progress overtime and are potentially fatal…

Understanding the rare disease framework is key to be able to offer study participants adapted solutions and as such, positively contribute to important and necessary clinical research conducted on rare diseases.

Kayentis offers an extensive experience in rare disease clinical trials, in indications such as:

  • Prader-Willi Syndrome
  • PIK3CA-related overgrowth spectrum
  • Auto-Immune Hepatitis (AIH)
  • Hypoparathyroidism
  • Sjögren’s syndrome
  • Acute Vertigo

#eCOA #ePRO #eDiary #rare disease #clinical trial

Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

Digital Biomarkers in Clinical Trials Summit

26 JUNE 2024 • ROCHE BUILDING 1 • BASEL
https://digitalbiomarkers.panagorapharma.com/    

Mobile in Clinical Trials

16 SEPT 2024 • Philadelphia, USA
https://mobileinclinicaltrials.com/

DPharm 2024

17-18 SEPT 2024 • Philadelphia, USA
https://dpharmconference.com/   

SCDM 2024

29 SEPT - 2 OCT 2024 • Boston, USA
https://scdmlive.org/annual-conference-2024/      

ISOQOL 2024

13-16 OCT 2024 • Cologne, Germany
https://www.isoqol.org/    

CNS SUMMIT 2024

10-13 NOV 2024 • Cologne, Germany
https://cnssummit.org/the-summit/  

DMB 2024

13 NOV 2024 • Paris, France
https://dmb-asso.org/

SCOPE 2025

FEB 3-6 2025 • Orlando, USA
Booth #931 https://www.scopesummit.com/